Effects of a cyproterone-containing oral contraceptive on hormonal levels in polycystic ovarian disease

J. Calaf-Alsina, J. Rodriguez-Espinosa, A. Cabero-Roura, O. Lenti-Paoli, J. Mora-Brugues, J. Esteban-Altirriba

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

The management of polycystic ovarian disease in women not desiring pregnancy is controversial. To avoid the progressive androgenic effects on peripheral target organs, some advocate the use of oral contraceptives. This study reports the effects of a preparation with 50 μg ethinyl estradiol and 2 mg cyproterone acetate on gonadotropins, prolactin, testosterone, sex hormone binding globulin (SHBG), androstenedione, and calculated free testosterone index before and after six months of treatment. Gonadotropins, testosterone, and androstenedione levels decreased, prolactin did not change, and sex hormone binding globulin increased as the result of the treatment. This led to a net decrease in the calculated free testosterone.
Original languageEnglish
Pages (from-to)255-258
JournalObstetrics and Gynecology
Volume69
Issue number2
Publication statusPublished - 13 Apr 1987

Fingerprint Dive into the research topics of 'Effects of a cyproterone-containing oral contraceptive on hormonal levels in polycystic ovarian disease'. Together they form a unique fingerprint.

  • Cite this

    Calaf-Alsina, J., Rodriguez-Espinosa, J., Cabero-Roura, A., Lenti-Paoli, O., Mora-Brugues, J., & Esteban-Altirriba, J. (1987). Effects of a cyproterone-containing oral contraceptive on hormonal levels in polycystic ovarian disease. Obstetrics and Gynecology, 69(2), 255-258.